CSAM News – October 2022

The CSAM News was recently published! Featured articles include Conference Photos, Like Minded Docs, President’s Message, CSAM 50th Anniversary Bash & More!

CSAM Sponsored Legislation Heads to the Governor for Signature

California Society of Addiction Medicine

One Capitol Mall, Suite 800, Sacramento, CA 95814 | 415/764-4855 | Fax 916/444-7462  www.csam-asam.org


A specialty society of physicians founded in 1973.  Since 1989, a State Chapter of the American Society of Addiction Medicine

FOR IMMEDIATE RELEASE

Contact: Kim Andosca
kandosca@amgroup.us

SB 57 (Wiener) – Overdose Prevention Program Passed by the California Senate

CSAM Sponsored Legislation Heads to the Governor for Signature

SACRAMENTO – The California Society of Addiction Medicine (CSAM) is pleased to announce that SB 57 (Wiener) was passed by the California Senate on August 1, and now heads to Governor Gavin Newsom for his consideration. The Governor has until the end of September to sign or veto the bills passed by the state Legislature at the end of this 2021/2022 legislative session.

SB 57, sponsored by CSAM and authored by Senator Scott Wiener (D-San Francisco), is life-saving legislation that would allow the City and County of San Francisco, the City and County of Los Angeles, and the City of Oakland the discretion to authorize overdose prevention programs where adults may use controlled substances under the supervision of staff trained to prevent and treat overdose, prevent HIV and hepatitis infection, and facilitate entry into drug treatment and other services. 

“The California Society of Addiction Medicine, which represents physicians who care for substance use disorders, is pleased that the California Senate has passed SB 57. Our organization is a co-sponsor of SB 57, and we believe this bill will save lives here in California,” said Randolph Holmes, MD, FAAFP, DFASAM, Chair of Public Policy for CSAM. “We urge Governor Newsom to sign this bill into law as quickly as possible so we can move forward with these necessary services for our community.”

Overdose prevention programs (OPPs) — also known as supervised consumption services (SCS) — such as those that could be established under this bill, provide a sanctioned, safe space for people to consume pre-obtained drugs in controlled settings under the supervision of trained staff. These staff have access to sterile consumption equipment and tools to check participants’ drug supply for the presence of fentanyl. Participants can also receive health care, counseling, and referrals to health and social services, including drug treatment.

“If Governor Newsom signs this bill into law, he will not only save uncounted lives from unnecessary death but will also create a pathway into treatment for thousands of Californians for whom there is currently little hope of recovery,” said David Kan, MD, DFASAM, Past President of CSAM.

###

The mission of CSAM is to advance the ethical and compassionate treatment of addiction through physician-led education of health professionals, patients, and the public. The Society promotes practice, research, prevention, and implementation of evidence-based treatment and sound drug policy. We advocate for our patients, their families, and other support systems at all stages of care.

More

FDA Responds to Dr. Albanese’s April 19, 2021 Letter

The FDA has responded to Dr. Albanese’s letter to them from April 19, 2021.

CLICK HERE to view the response!

FDA Commits to Evidence-Based Actions Aimed at Saving Lives and Preventing Future Generations of Smokers

FDA NEWS RELEASE:
April 29, 2021

FDA Commits to Evidence-Based Actions Aimed at Saving Lives and Preventing Future Generations of Smokers

Efforts to ban menthol cigarettes, ban flavored cigars build on previous flavor ban and mark significant steps to reduce addiction and youth experimentation, improve quitting, and address health disparities

Today, the U.S. Food and Drug Administration announced it is committing to advancing two tobacco product standards to significantly reduce disease and death from using combusted tobacco products, the leading cause of preventable death in the U.S. The FDA is working toward issuing proposed…

Read the Full Article…

More

CSAM Newsletter – Vol. 45 Issue #2 (Winter 2020)

The Newest Issue of the CSAM Newsletter is available. If you haven’t seen it yet, CLICK HERE to read it!

This issue features the President’s message by CSAM President, Anthony Albanese; 2020 Public Policy Report; and Updates from the Education Committee!

The ABPM & ASAM Announce a Four-Year Extension of the Practice Pathway for Addiction Medicine

Chicago, IL, November 30, 2020: The American Board of Preventive Medicine (ABPM) and the American Society of Addiction Medicine (ASAM) jointly announced today the American Board of Medical Specialties’ (ABMS) approval of a four-year extension of the practice…

Click Here to Read the entire article.

DEA Issues Interim Final Rule Clarifying MAT Dispensing

The Drug Enforcement Administration (DEA) issued an Interim Final Rule to clarify sections of the 2018 SUPPORT for Patients and Communities Act. The provisions in the Rule seek to further expand providers’ abilities to prescribe medication assisted treatment (MAT) to individuals suffering from opioid use disorders.

Key items addressed in the Rule include:

  1. Providers can prescribe MAT for up to 100 patients immediately, if the provider holds credentialing in addiction medicine or provides MAT using covered medications in a qualified practice setting. This updates prior rules which mandated a waivered provider could only treat up to 30 patients in their first year of the waiver before applying to treat up to 100 patients.
  2. Nurse practitioners and physician assistants had previously been granted the ability to be waivered to prescribe MAT on a temporary basis. The Interim Final Rule made this provision permanent.
  3. The definition of a “qualifying provider” eligible to prescribe MAT was expanded to include clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives. These providers are eligible to prescribe MAT on a temporary basis, through October 1, 2023. Waivered providers are eligible to treat up to 30 patients.
  4. A physician is eligible to receive a waiver to prescribe MAT if the physician recently graduated from a medical school that included at least 8 hours of training on treating and managing opioid-dependent patients.This shifts new waivers from post-residency continuing medical education to medical school or residency training.
  5. Pharmacies can permanently provide medications for maintenance or detoxification treatment to providers’ registered locations for use in treatment. Pharmacies previously were only allowed to deliver medications to the ultimate user or research subject.

Please send feedback on the Interim Final Rule to Chris Regal (cregal@ahip.org) by December 3. We will circulate draft comments prior to the December 10 Opioid Addiction Prevention and Treatment Work Group meeting. 

We look forward to your feedback. Please be in touch with questions. Thank you.

Article provided by AHIP.

Press Release: Gov. Newsom, Lt. Gov. Kounalakis To California: Beware Big Tobacco’s Lies and Deception to Overturn Landmark Law to Protect Kids

Click Here to read the Press Release.

CSAM Newsletter Winter 2019 Issue

Winter 2019 CSAM Newsletter

  • An Interview with CSAM’s New President Dr. Anthony Albanese – Pgs. 1-2; 7
  • Low Barrier Buprenorphine for Opioid Use Disorder: A Feasible Strategy to Save Lives and Livelihoods – Pgs. 3; 11
  • CSAM Addiction Medicine Review Course and Board Exam Preparation Track 2019 – Pgs. 4-5
  • Timmen Cermak, MD Receives Vernelle Fox Award – Pg. 6
  • CSAM’s Membership Now Tops 700! – Pg. 6
  • CSAM Community Service Award Goes to David Lisonbee, CEO of Twin Town Treatment Centers – Pg. 7
  • MERF Provides 54 Scholarships to 2019 Addiction Medicine Review Course in Anaheim – Pgs. 8-9
  • Highlights of the CSAM Leadership Development Retreat at Asilomar – Pgs. 10-11
  • CSAM Board of Directors Election Results Announced – Pg. 12
  • CSAM Executive Director to Retire in 2020 – Pg. 13
  • Newly Released: Guidelines for Physicians Working in California Opioid Treatment Programs – Pg. 13
  • Welcome New CSAM Members! – Pg. 14
  • CSAM Opposes Changes to Confidentiality of Substance Use Disorder Patient Records (42 CFR Part 2) – Pg. 15
  • CSAM’s Addiction Medicine Review Course is Now Available Online! – Pg. 15
  • State of the Art in Addiction Medicine Conference | August 26-29, 2020 – Pg. 16

Governor signs two addiction treatment reform measures, vetoes two others

This past week Governor Gavin Newsom signed AB-919 (Petrie-Norris) which promises to crack down on financial conflicts-of-interest among rehab operators by limiting how they offer housing and transportation as inducements to treatment. It will require that laboratories that test blood or urine for drugs, or outpatient treatment programs that offer housing to clients, have separate housing contracts specifically stating that payment for housing is the patient’s responsibility and rent should not be indirectly billed to health insurance. The practice has become common in the industry. It also empowers the CA Department of Health Care Services (DHCS) to provide enforcement with seven new positions, costing $1.2 million the first year and $1.1 million after that.

The Governor also signed AB-290 (Wood) which attempts to prevent third party payer tactics designed to steer patients into more expensive insurance plans for dialysis and substance use disorder treatment. Basically, it reduces the financial incentive to lure people to California by promising “free” insurance coverage.

SB-445 (Portantino) was vetoed by Governor Newsom with this message:  “To the Members of the California State Senate: I am returning Senate Bill 445 without my signature. SB 445 would require the Department of Health Care Services (DHCS) to establish youth substance use disorder treatment quality standards including certification requirements for programs and professionals, and convene a workgroup to advise the Department on quality standards. Although I support the author’s intent to strengthen substance use disorder treatment services for youth, implementation of this bill requires significant General Fund spending that should be considered through the annual budget process. I encourage the author and stakeholders to engage with DHCS’s recently-formed Behavioral Health Stakeholder Advisory Committee to address concerns regarding youth substance use disorder treatment services. Sincerely, Gavin Newsom”

AB-920 (Petrie-Norris) was also vetoed: “To the Members of the California State Assembly: I am returning Assembly Bill 920 without my signature. This bill would eliminate an existing voluntary outpatient certification program. Beginning January 1, 2021, it would attempt to require an outpatient substance use disorder (SUD) recovery or treatment services facility which is not licensed under existing law, to obtain licensure from the Department of Health Care Services (DHCS) to provide SUD services. The bill attempts to do this by replacing references to program certification in existing Health and Safety Code references to program licensure. I am supportive of the Legislature’s intent to license all SUD recovery and treatment services. However, developing a new licensing schema is a significant undertaking, and would require a significant departure from the bill as enrolled. This bill would need to be revised to provide adequate statutory authority for DHCS to effectively monitor and ensure compliance with outpatient licensure requirements. In addition, establishing the associated administrative oversight is not without significant cost. After reviewing this bill, it is clear that a substantial amount of work is still needed to develop a program that my administration can implement. As such, I recommend the Legislature and sponsors of this bill work closely with DHCS on a more robust proposal for my consideration. Costs for implementation of such a bill would need to be considered in the budget process. Sincerely, Gavin Newsom”